Terutroban

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Terutroban
Terutroban acid skeletal.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Biological half-life 6–10 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.107.361
Chemical and physical data
Formula C20H22ClNO4S
Molar mass 407.911 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Terutroban is an antiplatelet agent developed by Servier Laboratories. It has been tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).[1] The study was prematurely stopped and thus it could not be determined whether terutroban has a better effect than aspirin.

Method of action[edit]

Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.[2][3]

References[edit]

  1. ^ Hennerici, M. G.; Bots, M. L.; Ford, I.; Laurent, S.; Touboul, P. J. (2010). "Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial". Cardiovascular Drugs and Therapy. 24 (2): 175–80. doi:10.1007/s10557-010-6231-2. PMC 2887499Freely accessible. PMID 20490906. 
  2. ^ H. Spreitzer (January 29, 2007). "Neue Wirkstoffe - Terutroban". Österreichische Apothekerzeitung (in German) (3/2007): 116. 
  3. ^ Sorbera, LA, Serradell, N, Bolos, J, Bayes, M (2006). "Terutroban sodium". Drugs of the Future. 31 (10): 867–873. doi:10.1358/dof.2006.031.10.1038241.